title: Comparison of tumor and normal tissue dose for accelerated partial breast irradiation using an electronic brachytherapy eBx source and an Iridium-192 source.
abstract: The objective of this study has been to compare treatment plans for patients treated with electronic brachytherapy (eBx) using the Axxent System as adjuvant therapy for early stage breast cancer with treatment plans prepared from the same CT image sets using an Ir-192 source. Patients were implanted with an appropriately sized Axxent balloon applicator based on tumor cavity size and shape. A CT image of the implanted balloon was utilized for developing both eBx and Ir-192 brachytherapy treatment plans. The prescription dose was 3.4 Gy per fraction for 10 fractions to be delivered to 1 cm beyond the balloon surface. Iridium plans were provided by the sites on 35 of the 44 patients enrolled in the study. The planning target volume coverage was very similar when comparing sources for each patient as well as between patients. There were no statistical differences in mean %V100. The percent of the planning target volume in the high dose region was increased with eBx as compared with Iridium (p < 0.001). The mean maximum calculated skin and rib doses did not vary greatly between eBx and Iridium. By contrast, the doses to the ipsilateral lung and the heart were significantly lower with eBx as compared with Iridium (p < 0.0001). The total nominal dwell times required for treatment can be predicted by using a combination of the balloon fill volume and planned treatment volume (PTV). This dosimetric comparison of eBx and Iridium sources demonstrates that both forms of balloon-based brachytherapy provide comparable dose to the planning target volume. Electronic brachytherapy is significantly associated with increased dose at the surface of the balloon and decreased dose outside the PTV, resulting in significantly increased tissue sparing in the heart and ipsilateral lung.
authors.affiliation: Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma, OK, USA. randall.holt@enloe.org
authors.forename: Salahuddin
authors.initials: S
authors.lastname: Ahmad
authors.forename: Daniel
authors.initials: D
authors.lastname: Johnson
authors.forename: Jessica R
authors.initials: JR
authors.lastname: Hiatt
authors.forename: D Timothy
authors.initials: DT
authors.lastname: Still
authors.forename: Eli E
authors.initials: EE
authors.lastname: Furhang
authors.forename: David
authors.initials: D
authors.lastname: Marsden
authors.forename: Frank
authors.initials: F
authors.lastname: Kearly
authors.forename: Damian A
authors.initials: DA
authors.lastname: Bernard
authors.forename: Randall W
authors.initials: RW
authors.lastname: Holt
mesh_terms: D001918:Brachytherapy / Q000295:instrumentation*; D001940:Breast / Q000528:radiation effects*; D001943:Breast Neoplasms / Q000532:radiotherapy*; D004583:Electrons; D005260:Female; D006321:Heart / Q000528:radiation effects*; D006801:Humans; D007496:Iridium Radioisotopes / Q000627:therapeutic use*; D008168:Lung / Q000528:radiation effects*; D019047:Phantoms, Imaging; D011874:Radiometry; D011879:Radiotherapy Dosage
chemical_list: D007496:Iridium Radioisotopes